Meeting
2022 ASCO Annual Meeting
Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
Presenter
Matias Rodrigo Chacon, MD
Instituto Medico Especializado Alexander Fleming
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Other GU Kidney and Bladder Cancer
Clinical Trial Registration Number
NCT04810078
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4621)
DOI
10.1200/JCO.2022.40.16_suppl.TPS4621
Abstract #
TPS4621
Poster Bd #
100b
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.
Speaker: Maria T. Bourlon, MD, MSc
Videos & Slides
2024 ASCO Annual Meeting
Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.
Speaker: Saby George, MD, FACP
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
Speaker: Saby George, MD, FACP
Videos & Slides
2015 ASCO Annual Meeting
A Phase III Study (CheckMate 017) of Nivolumab (Anti-Programmed Death-1) vs Docetaxel in Previously Treated Advanced or Metastatic Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
Speaker: David R. Spigel, MD